Arena Pharmaceuticals (ARNA) rocketed by nearly 30% late Monday after its inflammatory bowel disease drug hit each of its goals in a midstage trial. In after …
Arena Pharmaceuticals, Inc. ARNA was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses …
Arena Pharmaceutical Inc. (ARNA) announced after the bell Monday that its Phase ... but traded in a range for the bulk of the session. The stock closed up by 8.86 at $39.75 with volume at an 8-month high. Arena Pharmaceutical jumped to …
A covered call identified by MarketIntelligececenter.com's patented algorithm on Arena Pharmaceuticals (ARNA) could yield about 4.82% (40.98% annualized, for comparison purposes only) in 43 days. Pair a long position in the stock with …
Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.
Shares of Arena Pharmaceuticals, Inc. closed the previous trading session at 1.19 down -0.01 -0.83% with 1,980,304 …
Arena Pharmaceuticals, Inc. ARNA was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent …
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.